At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 36 enrolled
Drug / intervention
ombitasvir/paritaprevir/ritonavir +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (TURQUOISE-CPB)
In Brief
A Phase 3 clinical trial evaluating ombitasvir/paritaprevir/ritonavir, dasabuvir, and 1 other intervention for Chronic Hepatitis C and 2 related conditions. Completed, enrolled 36 participants.
Detailed Summary
The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartNov 2014
Primary CompletionJun 2016
Study CompletionMar 2017
TodayJul 2026
First PostedAug 19, 2014
Enrollment StartNov 24, 2014
Primary CompletionJun 13, 2016
Study CompletionMar 3, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.9 years ago
Interventions
ombitasvir/paritaprevir/ritonavirdrug
tablet; paritaprevir co-formulated with ritonavir and ombitasvir
dasabuvirdrug
tablet
ribavirindrug
tablet